NervGen Pharma Corp. (NGEN)
| Market Cap | 206.03M +10.6% |
| Revenue (ttm) | n/a |
| Net Income | -29.98M |
| EPS | -0.40 |
| Shares Out | 106.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,131,969 |
| Open | 2.080 |
| Previous Close | 2.070 |
| Day's Range | 1.910 - 2.100 |
| 52-Week Range | 1.500 - 6.300 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 11.21 (+477.84%) |
| Earnings Date | May 22, 2026 |
About NGEN
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Co... [Read more]
Analyst Summary
According to 6 analysts, the average rating for NGEN stock is "Buy." The 12-month stock price target is $11.21, which is an increase of 477.84% from the latest price.
News
NervGen Pharma files $250M mixed securities shelf
09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study. Key highlights: NVG-2...
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma 24M share Spot Secondary priced at $2.50
Leerink and TD Cowen acted as joint book running managers for the offering.
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma secondary being re-offered at $2.50 per share
Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.
NervGen Pharma announces common share offering, no amount given
NervGen Pharma (NGEN) Corp. announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to…
NervGen Announces Proposed Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
“With the achievement of FDA alignment on the study parameters of RESTORE, our registrational study of NVG-291 in chronic tetraplegia, NervGen is now firmly in execution mode,” said Adam Rogers,…
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma appoints Keith Vendola as CFO
NervGen announced the appointment of Keith Vendola as CFO, effective immediately. Vendola will lead the company’s financial strategy and operations, including capital markets activity, financial plann...
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company is developing therapies for devastating neurological condition...
NervGen Pharma initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company’s lead clinical candidate, NVG-291, is about to enter a pivotal trial for…
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma price target raised to $12 from $10 at Maxim
Maxim raised the firm’s price target on NervGen Pharma (NGEN) to $12 from $10 and keeps a Buy rating on the shares, citing alignment with the FDA on RESTORE, the…
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
NervGen Pharma (NGEN) announced the completion of an End-of-Phase 2 meeting with the FDA and alignment on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for the…
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
Stifel lowered the firm’s price target on NervGen Pharma (NGEN) to $5.50 from $6.75 and keeps a Buy rating on the shares after having hosted an update with NervGen’s CEO…
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma to delist shares from TSX
NervGen Pharma (NGEN) announced that the company has elected to voluntarily delist its common shares from TSX Venture Exchange, effective at the close of markets on March 16. Published first…
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fir...
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel
Stifel raised the firm’s price target on NervGen Pharma (NGEN) to C$6.75 from C$5 and keeps a Buy rating on the shares.
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
NervGen Pharma (NGEN) appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President, SVP, Patient Advocacy and Clinical Affairs. Most recently, Ruff served ...
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fir...